Drug discontinuation: Lasmiditan Succinate Tablet (REYVOW)
FDA lists 6 presentations as To Be Discontinued. Companies: Eli Lilly and Co..
- Published by source
- 2025-11-03
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Eli Lilly and Co.
- Products
- Lasmiditan Succinate Tablet REYVOW
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2025-11-03
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #937 | new | 2026-10-22 | 95525d64dc25…d49ea7 | 3e4bc6968483…b3a873 |
Chain head: #1076 8ad5adc30b9b…88ce20